We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.

Just as bricks are key components in constructing a building, molecules known as amino acids are essential components in constructing proteins in the body. Recently, researchers in Japan investigated the role of a particular group of amino acids, known as D-amino acids, in the progression of viruses like influenza A virus (IAV) and Sars CoV-2, the virus responsible for COVID-19. N-Acetyl Tyrosine Powder

In a new study published in BBA - Molecular Basis of Disease, the research team have uncovered a relationship between D-amino acids and severe viral infection in both animals and humans.

While our understanding of COVID-19 has evolved during the COVID-19 pandemic, methods to predict disease severity and treat severe COVID-19 infection have been somewhat limited. D-amino acids have been previously shown to function as biomarkers for diseases such as kidney disease. However, the significance of D-amino acids in viral infection has not yet been explored, spurring the research team to investigate whether D-amino acids are affected during severe IAV infection or COVID-19.

We first assessed serum levels of D-amino acids in a mouse model of severe IAV infection and found that D-amino acids were greatly reduced in these mice compared with uninfected mice. When we evaluated serum from patients with severe COVID-19, we also found reduced levels of D-amino acids compared to those of healthy control subjects."

Shihoko Kimura-Ohba, lead author of the study

The researchers next explored the effects of supplementation with a specific D-amino acid known as D-alanine in mouse models of IAV infection and COVID-19. IAV mice exhibited a severe reduction in body weight that was mitigated by D-alanine treatment, while survival rates were improved in COVID-19 mice who received D-alanine treatment.

"Our results indicate that D-amino acids may serve as biomarkers to reflect the severity of viral infection," says senior author Tomonori Kimura. "Additionally, although the observed effects of D-alanine supplementation were limited, treatment with D-alanine may help to improve clinical outcomes in patients with severe viral infection."

The mechanism of D-alanine in the improvement of viral prognosis has yet to be elucidated. However, the research team's findings indicate that D-amino acids represent promising biomarkers and therapeutic options for the evaluation and treatment of severe viral infections, including those associated with COVID-19.

Kimura-Ohba, S., et al. (2022) D-Alanine as a biomarker and a therapeutic option for severe influenza virus infection and COVID-19. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. doi.org/10.1016/j.bbadis.2022.166584.

Tags: Alanine, Amino Acid, Biomarker, covid-19, Influenza, Kidney, Kidney Disease, Mouse Model, Nutrition, Pandemic, Research, SARS, Virus

At MEDICA 2022, NewsMedical spoke with Andreas Wuersig from Fraunhofer ISIT about the current and potential applications of their battery research and technology in the medical sector.

In this interview conducted by NewsMedical, IDEA Bio-Medical explains the many advantages of using zebrafish in microscopy.

Serge Mostowy and Sydney Miles

In this interview, NewsMedical speaks with Professor Serge Mostowy and Sydney Miles about their research on bacterial infection, and, in particular, on Shigella Flexneri and enteropathogens.

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

This site complies with the HONcode standard for trustworthy health information: verify here.

News-Medical.net - An AZoNetwork Site

China Qige Supply L-Alanine Cas 56-41-7 Owned and operated by AZoNetwork, © 2000-2022